ИИ ежедневно анализирует ведущие российские и международные источники, отбирает значимые исследования, рекомендации и новости и представляет их врачу в кратком структурированном формате.
Конференции, вебинары и симпозиумы по онкологии от ведущих организаций мира.
Организатор: Инновационная онкология
Организатор: ASTCT Meetings
Организатор: ESMO Meeting Calendar
Организатор: Инновационная онкология
Организатор: MASCC Supportive Care Events
Организатор: College of American Pathologists (CAP) Events
Организатор: ESGO Meeting Calendar
Организатор: SITC Events
Организатор: ESMO Meeting Calendar
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Организатор: EORTC
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Организатор: EAU
Организатор: EAU
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
These slides cover the evolving role of GPRC5D-directed bispecific antibodies in relapsed/refractory multiple myeloma. Take a look at evidence supporting CAR T-cell therapies and bispecific antibodies across the treatment continuum and explore considerations for treatment selection and sequencing of GPRC5D-directed therapy in the current treatment landscape, emerging data for talquetamab-based strategies, and factors that may influence outcomes following prior targeted therapy. The activity also addresses practical approaches to GPRC5D-directed bispecific antibody dosing, toxicity prevention, management, and patient counseling to support safe and effective integration of talquetamab into clinical practice.
Организатор: Decera Clinical
Downloadable slides on the evolving ADC landscape in the management of patients with HER2-negative metastatic breast cancer, current role of TROP2-directed ADCs, efficacy and safety of TROP2-directed ADCs in advanced breast cancer, ways to optimize adverse event recognition, early intervention and quality-of-life preservation for patients receiving TROP2-directed ADCs, key ongoing trials of TROP2-directed ADCs in breast cancer, role of nurses in providing optimal care for patients receiving ADCs, and multidisciplinary team coordination and shared decision-making to improve patient care.
Организатор: Decera Clinical
This activity reviews emerging and practice-informing clinical trial data across early and advanced breast cancer, with a focus on biomarker-guided treatment selection, endocrine resistance, targeted therapy combinations, and antibody–drug conjugates (ADCs). It examines recent evidence from OPTIMA, NATALEE, SERENA-6, ELEVATE, PIKALO-1, ASCENT-04 and -03, and TROPION-Breast02 presented at the 2026 ASCO Annual Meeting, including efficacy, safety, patient-reported outcomes, genomic and ctDNA biomarkers, and treatment-sequencing considerations. The clinically relevant content contains data that may help learners determine when chemotherapy can be safely omitted, when molecular findings should prompt a change in therapy, how to incorporate newer targeted agents and ADCs, and how to individualize treatment choices based on disease subtype, genomic risk, prior therapy, and toxicity profiles.
Организатор: Decera Clinical
Treatment of head and neck squamous cell carcinoma (HNSCC) continues to evolve across curative-intent and recurrent or metastatic settings, leading to new questions on how emerging evidence should be incorporated into clinical practice. In this changing therapeutic landscape, experts examine the clinical implications of HPV-associated vs HPV-unrelated disease, integration of perioperative immunotherapy together with established multimodality care, treatment selection in recurrent or metastatic HNSCC, and the emerging role of novel EGFR-directed therapies. In addition, the experts provide their insights on toxicity management, supportive care, and multidisciplinary strategies to preserve function and quality of life throughout the treatment continuum.
Организатор: Decera Clinical
This activity examines evidence-based selection and management of adjuvant systemic therapy for patients with high-risk HR-positive/HER2-negative early breast cancer, with emphasis on recurrence risk stratification, eligibility for CDK4/6 inhibitors, and treatment tolerability. The expert discussion highlights long-term distant recurrence risk after endocrine therapy and phase III data from monarchE and NATALEE, including survival, patient selection criteria, treatment duration, and distinct safety profiles for adjuvant abemaciclib and ribociclib. It also addresses emerging phase III evidence for the oral SERD giredestrant. Practical case-based scenarios highlight how anatomic stage, nodal status, tumor grade, Ki-67, genomic risk, BRCA status, guideline criteria, toxicity profiles, and patient preferences influence treatment choice, and additional content focuses on monitoring and managing adverse events to support dose optimization and adherence.
Организатор: Decera Clinical
In this commentary, expert faculty reviews the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), with emphasis on biomarker-driven therapy, combination strategies, radiopharmaceuticals, and emerging approaches for overcoming resistance. The faculty also examines real-world gaps in germline and somatic testing; phase III data supporting PARP inhibitor/ARPI combinations, PSMA-targeted radioligand therapy, and radium-223 plus enzalutamide; and the role of PTEN-directed AKT inhibition in advanced prostate cancer. Investigational approaches targeting EZH2, CYP11A1, mutant or persistent androgen receptor signaling, and tumor-associated cell-surface targets are also highlighted. Together, these data underscore the importance of early comprehensive biomarker testing, appropriate sequencing of established therapies, toxicity and supportive care considerations, and clinical trial participation when standard options are limited.
Организатор: Decera Clinical
In this text module, an expert examines the evolving role of GPRC5D-directed bispecific antibodies in relapsed/refractory multiple myeloma, with a focus on evidence supporting bispecific antibodies and emerging CAR T-cell therapies across the treatment continuum. Learners will explore considerations for treatment selection and sequencing of GPRC5D-directed therapy in the current treatment landscape, emerging data for talquetamab-based strategies, and factors that may influence outcomes following prior targeted therapy. The activity also addresses practical approaches to GPRC5D-directed bispecific antibody dosing, toxicity prevention and management, and patient counseling to support safe and effective integration of talquetamab into clinical practice.
Организатор: Decera Clinical
These slides cover the evolving role of GPRC5D-directed bispecific antibodies in relapsed/refractory multiple myeloma. Take a look at evidence supporting CAR T-cell therapies and bispecific antibodies across the treatment continuum and explore considerations for treatment selection and sequencing of GPRC5D-directed therapy in the current treatment landscape, emerging data for talquetamab-based strategies, and factors that may influence outcomes following prior targeted therapy. The activity also addresses practical approaches to GPRC5D-directed bispecific antibody dosing, toxicity prevention, management, and patient counseling to support safe and effective integration of talquetamab into clinical practice.
Организатор: Decera Clinical
Downloadable slides on the evolving ADC landscape in the management of patients with HER2-negative metastatic breast cancer, current role of TROP2-directed ADCs, efficacy and safety of TROP2-directed ADCs in advanced breast cancer, ways to optimize adverse event recognition, early intervention and quality-of-life preservation for patients receiving TROP2-directed ADCs, key ongoing trials of TROP2-directed ADCs in breast cancer, role of nurses in providing optimal care for patients receiving ADCs, and multidisciplinary team coordination and shared decision-making to improve patient care.
Организатор: Decera Clinical
This activity reviews emerging and practice-informing clinical trial data across early and advanced breast cancer, with a focus on biomarker-guided treatment selection, endocrine resistance, targeted therapy combinations, and antibody–drug conjugates (ADCs). It examines recent evidence from OPTIMA, NATALEE, SERENA-6, ELEVATE, PIKALO-1, ASCENT-04 and -03, and TROPION-Breast02 presented at the 2026 ASCO Annual Meeting, including efficacy, safety, patient-reported outcomes, genomic and ctDNA biomarkers, and treatment-sequencing considerations. The clinically relevant content contains data that may help learners determine when chemotherapy can be safely omitted, when molecular findings should prompt a change in therapy, how to incorporate newer targeted agents and ADCs, and how to individualize treatment choices based on disease subtype, genomic risk, prior therapy, and toxicity profiles.
Организатор: Decera Clinical
Treatment of head and neck squamous cell carcinoma (HNSCC) continues to evolve across curative-intent and recurrent or metastatic settings, leading to new questions on how emerging evidence should be incorporated into clinical practice. In this changing therapeutic landscape, experts examine the clinical implications of HPV-associated vs HPV-unrelated disease, integration of perioperative immunotherapy together with established multimodality care, treatment selection in recurrent or metastatic HNSCC, and the emerging role of novel EGFR-directed therapies. In addition, the experts provide their insights on toxicity management, supportive care, and multidisciplinary strategies to preserve function and quality of life throughout the treatment continuum.
Организатор: Decera Clinical
This activity examines evidence-based selection and management of adjuvant systemic therapy for patients with high-risk HR-positive/HER2-negative early breast cancer, with emphasis on recurrence risk stratification, eligibility for CDK4/6 inhibitors, and treatment tolerability. The expert discussion highlights long-term distant recurrence risk after endocrine therapy and phase III data from monarchE and NATALEE, including survival, patient selection criteria, treatment duration, and distinct safety profiles for adjuvant abemaciclib and ribociclib. It also addresses emerging phase III evidence for the oral SERD giredestrant. Practical case-based scenarios highlight how anatomic stage, nodal status, tumor grade, Ki-67, genomic risk, BRCA status, guideline criteria, toxicity profiles, and patient preferences influence treatment choice, and additional content focuses on monitoring and managing adverse events to support dose optimization and adherence.
Организатор: Decera Clinical
In this commentary, expert faculty reviews the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), with emphasis on biomarker-driven therapy, combination strategies, radiopharmaceuticals, and emerging approaches for overcoming resistance. The faculty also examines real-world gaps in germline and somatic testing; phase III data supporting PARP inhibitor/ARPI combinations, PSMA-targeted radioligand therapy, and radium-223 plus enzalutamide; and the role of PTEN-directed AKT inhibition in advanced prostate cancer. Investigational approaches targeting EZH2, CYP11A1, mutant or persistent androgen receptor signaling, and tumor-associated cell-surface targets are also highlighted. Together, these data underscore the importance of early comprehensive biomarker testing, appropriate sequencing of established therapies, toxicity and supportive care considerations, and clinical trial participation when standard options are limited.
Организатор: Decera Clinical
Организатор: ESMO Meeting Calendar
Организатор: ESMO Meeting Calendar
Организатор: ESMO Meeting Calendar
Организатор: College of American Pathologists (CAP) Events
Организатор: ESGO Meeting Calendar
Организатор: ESTRO
Организатор: ESTRO
In this on-demand webcast, an expert reviews contemporary treatment strategies for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with an emphasis on how prior therapy, mechanisms of resistance, comorbidities, disease characteristics, and patient preferences inform treatment sequencing. The faculty examines evidence supporting covalent and noncovalent BTK inhibitors, BCL-2 inhibitor–based regimens, and retreatment approaches; discusses pivotal trials including MURANO, ELEVATE-RR, ALPINE, and the BRUIN CLL studies; and addresses the evolving role of pirtobrutinib and CAR T-cell therapy for patients with increasingly treatment-resistant disease. The activity also reviews practical management of treatment-related toxicities, including tumor lysis syndrome, bleeding, atrial fibrillation, hypertension, and infusion reactions, as well as strategies to prevent disease flare when transitioning between therapies. Finally, emerging approaches such as BTK degraders and bispecific antibodies are considered alongside patient-centered factors, providing learners with a framework for individualizing therapy across successive lines of CLL/SLL treatment.
Организатор: Decera Clinical
Организатор: Decera Clinical
In this on-demand webcast, experts review current standards and emerging evidence for HER2 testing and HER2-directed therapy in advanced gastroesophageal adenocarcinoma and biliary tract cancer, with emphasis on how biomarker results should guide treatment selection and sequencing. Experts also discuss guideline-based HER2 assessment, clinical implications of intratumoral HER2 heterogeneity and loss of HER2 expression after treatment, and the rationale for reassessing HER2 status at progression. Pivotal and emerging clinical trial data for trastuzumab-, zanidatamab-, and trastuzumab deruxtecan–based strategies are summarized, and faculty address how efficacy, PD-L1 status, prior therapy, comorbidities, and toxicity profiles may influence treatment decisions. Practical management of treatment-related toxicities, particularly zanidatamab-associated diarrhea and infusion-related reactions and trastuzumab deruxtecan–associated interstitial lung disease/pneumonitis, is also discussed to support safe implementation of HER2-targeted therapy in clinical practice.
Организатор: Decera Clinical
In this on-demand webcast, an expert reviews the evidence supporting low-dose CT screening for lung cancer and examines how current eligibility criteria, risk factors, and implementation barriers affect early detection in clinical practice. The activity highlights landmark randomized data from NELSON and the National Lung Screening Trial demonstrating reductions in lung cancer mortality with screening while comparing current screening guidelines for eligibility. The expert also explores limitations of age- and pack-year–based criteria, disparities in screening access and eligibility, and emerging evidence supporting broader risk assessment that incorporates factors such as family history, occupational and environmental exposures, race and ethnicity, and risk prediction models. Practical strategies for improving screening uptake, including shared decision-making, centralized screening programs, navigation, electronic health record prompts, and patient-centered communication, are discussed alongside emerging approaches that may help identify high-risk individuals who fall outside current screening guidelines.
Организатор: Decera Clinical
Организатор: MASCC Supportive Care Events
Организатор: EBMT Educational Events & Meetings
Организатор: Oncopulm
Организатор: European Congress of Pathology (ECP)
Организатор: European Congress of Pathology (ECP)
Организатор: College of American Pathologists (CAP) Events
Организатор: European Congress of Pathology (ECP)
Организатор: European Society of Pathology — Events
Организатор: SNMMI Upcoming Events
Форум посвящён 155-летию со дня рождения П.А. Герцена. Организаторы — ФГБУ «НМИЦ радиологии» Минздрава России, Ассоциация онкологов России (АОР), Российская ассоциация терапевтических радиационных онкологов (РАТРО) и АДИОР стран СНГ и Евразии. Основные тематики: организация онкологической помощи и подготовка кадров; скрининги и лучевая диагностика; радиотерапия и медицинская физика; паллиативная помощь и реабилитация; патоморфология и молекулярно-генетические исследования; онкоиммунология и противоопухолевая лекарственная терапия. 15 сентября — вручение премии им. академика А.И. Савицкого. Участие бесплатное.
Организатор: НМИЦ радиологии Минздрава России, АОР, РАТРО, АДИОР
In this podcast, experts review 2 of the most important studies presented at the ASCO 2026 annual conference that inform treatment decisions for patients with early-stage hormone receptor–positive/HER2-negative breast cancer. The discussion focuses on the phase III OPTIMA trial, which evaluated Prosigna PAM50-guided chemotherapy selection and the potential for chemotherapy de-escalation in selected patients, with stimulating insights on the role of ovarian function suppression with endocrine therapy in premenopausal women. Their discussion also examines the NATALEE PAM50 biomarker analysis, which demonstrated benefit from adjuvant ribociclib across intrinsic molecular breast cancer subtypes without a significant treatment-by-subtype interaction. Together, these findings help clarify how genomic risk assessment, menopausal status, tumor biology, and adjuvant CDK4/6 inhibitor therapy may be integrated into individualized treatment planning and shared decision-making.
Организатор: Decera Clinical
Review certified expert analysis text modules, podcasts, and Capsule Summaries highlighting key studies from the 2025 ASH annual meeting.
Организатор: Decera Clinical
Организатор: College of American Pathologists (CAP) Events
Организатор: ESTRO
Организатор: College of American Pathologists (CAP) Events
In this podcast episode, experts discuss the scientific rationale and emerging clinical evidence for targeting CDH6 in platinum-resistant ovarian cancer, with a focus on CDH6-directed antibody–drug conjugates (ADCs) such as raludotatug deruxtecan and other investigational agents. The discussion examines CDH6 expression in ovarian tumors, the current limitations of biomarker testing and patient selection, and how ADC characteristics, including target expression, payload, linker properties, and drug-to-antibody ratio, may influence efficacy. Experts also review early clinical activity and key toxicities associated with CDH6-directed ADCs, including cytopenias, gastrointestinal adverse events, fatigue, and interstitial lung disease, and emphasize monitoring and supportive care considerations. The conversation further explores unresolved questions about ADC sequencing, potential cross-resistance between agents sharing topoisomerase I inhibitor payloads, changes in tumor biomarker expression over time, and the potential role of repeat biopsy in guiding treatment selection as additional targeted therapies become available.
Организатор: Decera Clinical
In this on-demand webcast, experts examine the evolving role of bispecific antibodies in multiple myeloma, with emphasis on how emerging efficacy, sequencing, resistance, and safety data can inform individualized treatment decisions. Faculty review evidence for BCMA-directed and GPRC5D-directed bispecific therapies across relapsed/refractory and earlier-line settings, including results from MajesTEC, MagnetisMM, LINKER-MM, MonumenTAL, and RedirecTT studies, and discuss how prior BCMA exposure, CAR T-cell eligibility, target switching, disease characteristics, and patient-specific barriers may influence therapeutic selection and sequencing. Mechanisms of resistance to BCMA-directed and GPRC5D-directed therapy and practical management of treatment-related toxicities, including cytokine release syndrome, ICANS, infections, hypogammaglobulinemia, and GPRC5D-associated oral, skin, and nail effects, are also addressed. Finally, faculty outline strategies for step-up dosing, infection prophylaxis, caregiver education, monitoring, and outpatient care infrastructure, providing learners with a practical framework for integrating bispecific antibodies safely and effectively into contemporary multiple myeloma practice.
Организатор: Decera Clinical
Get practical guidance on a wide range of hematologic malignancies at this exciting satellite symposia held both in-person in New Orleans and virtually.
Организатор: Decera Clinical
Get access to presentation slidesets, on-demand webcasts, and expert commentaries on oncology & hematology topics.
Организатор: Decera Clinical
With Decera Clinical Education (formerly CCO) access the latest oncology CME/CE activities and live events on breast, lung, hematologic, and other cancer types. Get evidence-based education for the entire oncology care team.
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
Организатор: Decera Clinical
The approach to immune thrombocytopenia treatment is evolving as updated guidance and emerging evidence support more individualized care. This faculty-led activity explores strategies to reduce corticosteroid exposure, navigate subsequent treatment options, address fatigue and quality of life alongside platelet response, and assess the potential for treatment tapering and treatment-free response.
Организатор: Decera Clinical
The care of patients with extensive-stage (ES) small-cell lung cancer (SCLC) continues to evolve with the continuous release of new clinical evidence. Listen to this podcast with 2 experts discussing current gaps and clinical needs for patients with relapsed ES-SCLC, the scientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLC, the expanding role of antibody–drug conjugates (ADCs) and T-cell engagers in ES-SCLC including recent efficacy and safety data for B7-H3–directed ADCs such as ifinatamab deruxtecan (I-DXd) in ES-SCLC and the strengths and limitations of the available evidence. The experts synthesize this information along with their clinical experiences to illustrate how they are individualizing the care of patients with ES-SCLC based on patient-specific characteristics that influence the selection and sequencing of treatment with a case-based discussion. They close with a reminder of the importance of discussing ongoing trials of investigational B7-H3–directed ADCs and other therapies in ES-SCLC with the goal of continuing to improve outcomes for patients with this disease.
Организатор: Decera Clinical
These slides review the pathophysiology, clinical consequences, risk assessment, prevention, and management of tumor lysis syndrome (TLS) in patients with hematologic malignancies, with an emphasis on identifying patients at increased risk and applying evidence-based monitoring, supportive care, and uric acid–lowering strategies. They address practical management of TLS-associated electrolyte abnormalities and the roles of allopurinol, febuxostat, and rasburicase, including dosing, safety, and patient-selection considerations. The slides also examine evolving TLS risks associated with newer therapies, including venetoclax, CAR T-cell therapy, and bispecific antibodies, and treatment-specific mitigation strategies such as dose ramp-up, prophylaxis, laboratory monitoring, and inpatient vs outpatient initiation. In addition, they highlight considerations for developing institutional TLS protocols to standardize risk stratification, prophylaxis, treatment initiation, and multidisciplinary management across clinical settings.
Организатор: Decera Clinical
CAR T-cell therapy is an established treatment option for patients with R/R B-cell lymphomas, but successful use requires timely referral, coordinated care, and proactive management of treatment-related toxicities. This slideset reviews current evidence and practical considerations for CAR T-cell therapy, including patient referral and preparation, treatment logistics, and strategies for recognizing and managing acute and late adverse events.
Организатор: Decera Clinical
Watch this on-demand webcast to explore the latest evidence and best practices for optimizing TKI therapy in chronic phase chronic myeloid leukemia (CP-CML), including individualized treatment selection and sequencing, molecular monitoring, and shared decision-making. Viewers will also examine practical strategies to improve treatment adherence and persistence and proactively identify and manage TKI-related adverse events.
Организатор: Decera Clinical
Explorez les données de phase III à l’origine des nouvelles autorisations réglementaires pour les ADC anti-TROP2 dans les cancers du sein métastatiques RH+ /HER2- et triple négatif, avec un focus sur les nouvelles données d'efficacité et de sécurité qui peuvent aider au choix de traitement. Découvrez les avis d'experts sur le choix du traitement de première ligne et des lignes ultérieures en fonction de l'éligibilité à l'immunothérapie et du profil d'événements indésirables des ADC ciblant TROP. Enfin, apprenez à anticiper et atténuer les éventuels effets indésirables susceptibles de limiter la poursuite du traitement, et quels soins de support proposer.
Организатор: Decera Clinical
Explore current and emerging phase III evidence for TROP2 ADCs in patients with metastatic triple-negative breast cancer who are ineligible for immunotherapy, including implications for patients and healthcare teams when selecting first-line and later-line treatments. Examine how patient characteristics, prior treatment exposure, comorbidities, and distinct adverse event profiles inform individualized care, along with multidisciplinary strategies for toxicity prevention, monitoring, supportive care, and dose modification.
Организатор: Decera Clinical
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: EBMT Educational Events & Meetings
Вебинар по актуальным вопросам диагностики и лечения рака лёгкого.
Организатор: RUSSCO
Организатор: EAU
Организатор: ESMO Meeting Calendar
Организатор: ESMO Meeting Calendar
Ежегодный конгресс Европейского общества медицинской онкологии. Новейшие клинические данные и инновационные методы лечения.
Организатор: ESMO
Организатор: College of American Pathologists (CAP) Events
Организатор: EAU
Организатор: НМИЦ радиологии Минздрава России
Организатор: ESTRO
Организатор: ESTRO
Организатор: ESMO Meeting Calendar
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: College of American Pathologists (CAP) Events
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: MASCC Supportive Care Events
Организатор: College of American Pathologists (CAP) Events
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Организатор: НМИЦ радиологии Минздрава России
Организатор: ASTCT Meetings
Организатор: НМИЦ радиологии Минздрава России
Организатор: ESGO Meeting Calendar
Организатор: MASCC Supportive Care Events
Организатор: Society for Neuro-Oncology — Events Calendar
Организатор: EBMT Educational Events & Meetings
Организатор: European School of Oncology (ESO)
Организатор: EAU
Организатор: European Society of Pathology — Events
Организатор: MASCC Supportive Care Events
Организатор: Society for Neuro-Oncology — Events Calendar
Организатор: EAU
Организатор: MASCC Supportive Care Events
Организатор: SIOP Community Calendar
Организатор: ESTRO
Организатор: ESMO Meeting Calendar
Организатор: MASCC Supportive Care Events
Организатор: ASTCT Meetings
Организатор: НМИЦ онкологии им. Н.Н. Петрова